Stock

Coherus Oncology, Inc. CHRS

$1.43-0.70%

All stocks Create account to unlock

Overview

CHRS market data

Price History

CHRS price chart

Valuation & Profitability

no valuation data

No Valuation Data Yet

Alpha Vantage and Twelve Data both returned no valuation metrics for CHRS. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.

Company news

5 captured

Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026 · Jul 22, 2026, 6:15 PM

Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi) · Jun 23, 2026, 6:15 PM

Coherus Announces Clinical Collaboration And Supply Agreement With Zumutor To Conduct Phase 1 Trial Of ZM008, NK Checkpoint Anti-LLT1 Monoclonal Antibody In Combination With LOQTORZI · Jun 23, 2026, 6:10 PM

8-K filing — Coherus Oncology, Inc. (CHRS) · Jun 15, 2026, 8:40 PM

Earnings Scheduled For May 11, 2026 · May 11, 2026, 11:11 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock